CD274 and neoplasm: Research has explored various biomarkers, such as PD-L1 score, tumor mutation burden (TMB), tumor-infiltrating lymphocytes (TILs), and microsatellite instability (MSI), to predict immunotherapy outcomes in solid tumors like those in the esophagus, breast, and intestines (7–9).